Annual report pursuant to Section 13 and 15(d)

Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)

v3.6.0.2
Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
 [1]
Sep. 30, 2015
 [1]
Jun. 30, 2015
 [1]
Mar. 31, 2015
 [1]
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues $ 524 $ 635 $ 443 $ 3,962 $ 48,183 $ 2,074 $ 2,539 $ 2,651 $ 5,564 $ 55,447 $ 18,866
United States [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 3,822 10,685 11,756
Europe [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 1,642 44,662 5,510
Asia Pacific [Member]                      
Revenues from External Customers and Long-Lived Assets [Line Items]                      
Revenues                 $ 100 $ 100 $ 1,600
[1] In the fourth quarter of 2015, total revenues include upfront and milestone payments relating to various out-licensing arrangements, including a $37.0 million upfront payment from Novartis, a $5.0 million upfront payment from Novo Nordisk and a $3.8 million payment from Pfizer.